Health and longevity are emerging as one of defining frontiers of health of the next decade. As populations age and chronic disease burdens rise, innovations in science and technology are reshaping how we understand – and potentially intervene in the biological processes that drive ageing. Breakthroughs in aging biology, AI-driven diagnostics, and preventive medicine are opening the door to interventions that could extend not just lifespan, but healthspan. How can pharmaceutical innovation, strategic capital, nutritional science, and technology platforms work together to translate advances in longevity science into scalable and sustainable he
Monday, May 4, 14:30 - 15:15, room Shanghai 1+2
| Name | Position | Institution |
|---|---|---|
| Andrea Feigl, PhD | Senior Director, Health Financing Strategy | Deloitte |
| Name | Position | Institution |
|---|---|---|
| Dr. Alexandra Vallon-Eberhard | Senior Director - CTO, Global Strategy & Partnering | Roche |
| Anne Marije van Harten, PhD | Investment Director | Apollo Health Ventures |
| Ricardo Gaminha Pacheco | Head of Strategic Partnerships | Insilico Medicine |
At Deloitte, we make an impact that matters. For over 180 years, we have worked with leaders around the world—from the Global 500® to private businesses—to help them build better futures. In the Life Sciences industry, the convergence of innovation in AI, digital health and patient data connectivity is blurring traditional boundaries. With our global network of expertise and engagement with the health ecosystem, we are positioned to help you to drive your business forward—not only because we understand complex problems, but because we have the multi-disciplinary solutions to help solve them. We go beyond talk—we do.
